Illumina (ILMN) Shares Gap Up to $242.80
Illumina, Inc. (NASDAQ:ILMN) gapped up before the market opened on Wednesday . The stock had previously closed at $248.83, but opened at $242.80. Illumina shares last traded at $240.74, with a volume of 455758 shares changing hands.
A number of brokerages have issued reports on ILMN. Evercore ISI began coverage on shares of Illumina in a research note on Wednesday, January 3rd. They set an “outperform” rating and a $250.00 target price for the company. Goldman Sachs Group reissued a “neutral” rating and set a $200.00 target price on shares of Illumina in a research note on Tuesday, September 26th. BTIG Research began coverage on shares of Illumina in a research note on Friday, January 5th. They set a “neutral” rating for the company. William Blair lowered shares of Illumina from an “outperform” rating to a “market perform” rating in a research note on Friday, January 5th. Finally, Wells Fargo & Co reissued a “positive” rating and set a $260.00 target price (up previously from $250.00) on shares of Illumina in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $214.38.
The company has a market cap of $35,050.00, a price-to-earnings ratio of 45.29, a P/E/G ratio of 3.13 and a beta of 0.79. The company has a quick ratio of 3.73, a current ratio of 4.22 and a debt-to-equity ratio of 0.41.
Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 EPS for the quarter, topping the consensus estimate of $0.99 by $0.12. The firm had revenue of $714.00 million for the quarter, compared to the consensus estimate of $692.77 million. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The business’s quarterly revenue was up 17.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.97 EPS. sell-side analysts expect that Illumina, Inc. will post 3.75 earnings per share for the current year.
In other news, EVP Marc Stapley sold 2,000 shares of the business’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $205.48, for a total transaction of $410,960.00. Following the transaction, the executive vice president now owns 30,370 shares in the company, valued at approximately $6,240,427.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Oene Mark Van sold 1,250 shares of the business’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $207.76, for a total transaction of $259,700.00. Following the transaction, the senior vice president now owns 11,691 shares in the company, valued at approximately $2,428,922.16. The disclosure for this sale can be found here. Insiders sold a total of 137,671 shares of company stock worth $29,485,768 in the last quarter. Insiders own 0.89% of the company’s stock.
Institutional investors have recently modified their holdings of the company. Dupont Capital Management Corp acquired a new position in Illumina in the third quarter valued at about $153,000. Advisory Services Network LLC boosted its position in Illumina by 13.0% in the second quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock valued at $134,000 after buying an additional 89 shares in the last quarter. West Coast Financial LLC acquired a new position in Illumina in the third quarter valued at about $216,000. Los Angeles Capital Management & Equity Research Inc. acquired a new position in Illumina in the second quarter valued at about $226,000. Finally, Colony Group LLC acquired a new position in Illumina in the second quarter valued at about $239,000. Institutional investors and hedge funds own 91.60% of the company’s stock.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.